Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

MannKind announced new clinical and real-world data for Afrezza (inhaled insulin) presented at the ADA 2026 Scientific Sessions, following the FDA approval for pediatric use (ages 6+) in May 2026. Key findings include greater treatment satisfaction in pediatric patients, comparable efficacy to rapid-acting analogs, potential use with automated insulin delivery systems, and earlier pharmacodynamic effect completion. The company also reported positive real-world evidence on lung cancer risk and FUROSCIX benefits in heart failure patients.